News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
225,686 Results
Type
Article (7116)
Company Profile (16)
Press Release (218554)
Section
Business (63109)
Career Advice (294)
Deals (14766)
Drug Delivery (27)
Drug Development (36768)
Employer Resources (24)
FDA (6405)
Job Trends (4906)
News (121761)
Policy (11620)
Tag
Academia (564)
Alliances (14739)
Alzheimer's disease (578)
Approvals (6423)
Artificial intelligence (84)
Bankruptcy (146)
Best Places to Work (4608)
Breast cancer (92)
Cancer (922)
Cardiovascular disease (54)
Career advice (256)
CAR-T (78)
Cell therapy (194)
Clinical research (30835)
Collaboration (255)
Compensation (68)
COVID-19 (715)
C-suite (58)
Data (1035)
Diabetes (86)
Diagnostics (2202)
Earnings (32848)
Events (30575)
Executive appointments (192)
FDA (6914)
Funding (220)
Gene therapy (113)
GLP-1 (164)
Government (1248)
Healthcare (6136)
Infectious disease (765)
Inflammatory bowel disease (56)
Interviews (45)
IPO (8010)
Job creations (570)
Job search strategy (220)
Legal (2094)
Lung cancer (127)
Lymphoma (61)
Manufacturing (83)
Medical device (4554)
Medtech (4555)
Mergers & acquisitions (7031)
Metabolic disorders (226)
Neuroscience (734)
NextGen: Class of 2025 (1506)
Non-profit (711)
Northern California (1056)
Obesity (117)
Opinion (71)
Parkinson's disease (47)
Patents (96)
People (14383)
Phase I (9828)
Phase II (13573)
Phase III (10174)
Pipeline (498)
Postmarket research (796)
Preclinical (3557)
Radiopharmaceuticals (116)
Rare diseases (139)
Real estate (999)
Regulatory (9012)
Research institute (509)
Southern California (897)
Startups (674)
United States (8851)
Vaccines (148)
Weight loss (67)
Date
Today (40)
Last 7 days (382)
Last 30 days (1192)
Last 365 days (16435)
2025 (2379)
2024 (16923)
2023 (19098)
2022 (22233)
2021 (23633)
2020 (21795)
2019 (14450)
2018 (10638)
2017 (11455)
2016 (9543)
2015 (11736)
2014 (8102)
2013 (5877)
2012 (6040)
2011 (6749)
2010 (6216)
Location
Africa (175)
Asia (17421)
Australia (4819)
California (2355)
Canada (986)
China (186)
Colorado (103)
Connecticut (140)
Delaware (47)
Europe (27658)
Florida (344)
Georgia (54)
Illinois (172)
Indiana (105)
Japan (76)
Maryland (293)
Massachusetts (1729)
Michigan (48)
Minnesota (90)
New Jersey (822)
New York (758)
North Carolina (346)
Northern California (1056)
Ohio (52)
Pennsylvania (564)
South America (300)
Southern California (897)
Texas (347)
Utah (57)
Virginia (61)
Washington State (310)
225,686 Results for "xstrahl limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Dynavax Adopts Limited-Duration Stockholder Rights Plan
October 30, 2024
·
5 min read
Press Releases
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
December 5, 2024
·
19 min read
Press Releases
Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine
February 25, 2025
·
6 min read
Cancer
BMS’ Phase III Opdualag Melanoma Fail Could Limit Market Opportunity: Analysts
The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.
February 14, 2025
·
2 min read
·
Tristan Manalac
Drug Development
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival and progression-free survival compared to placebo for patients with limited-stage small cell lung cancer who had not progressed following standard-of-care concurrent chemoradiotherapy.
June 2, 2024
·
27 min read
Press Releases
Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering
January 8, 2025
·
4 min read
Press Releases
Piramal Pharma Limited Announces Results for Q3 and 9M FY25
January 29, 2025
·
6 min read
Press Releases
Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®
February 11, 2025
·
8 min read
Press Releases
Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters’ Over-Allotment Option
January 14, 2025
·
4 min read
Drug Development
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival and progression-free survival in patients with limited-stage small cell lung cancer who had not progressed following concurrent chemoradiotherapy compared to placebo after cCRT.
April 5, 2024
·
26 min read
1 of 22,569
Next
